Terms: = Prostate cancer AND AFP, AFPD, FETA, HPAFP
131 results:
1. Relevance of blood tumor markers in inpatients with significant involuntary weight loss and elevated levels of inflammation biomarkers.
Gronnier M; Hedhli K; Sauzay C; Salle V; Duhaut P; Schmidt J; Dernoncourt A
BMC Cancer; 2024 Apr; 24(1):468. PubMed ID: 38622530
[TBL] [Abstract] [Full Text] [Related]
2. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
3. Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost-effectiveness analysis.
Nan Y; Garay OU; Lu X; Zhang Y; Xie L; Niu Z; Chen W
J Comp Eff Res; 2024 Apr; 13(4):e230146. PubMed ID: 38415341
[No Abstract] [Full Text] [Related]
4. Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study.
van Rossum HH; Holdenrieder S; Ballieux BEPB; Badrick TC; Yun YM; Zhang C; Patel D; Thelen M; Song J; Wojtalewicz N; Unsworth N; Vesper HW; Cui W; Ramanathan LV; Sturgeon C; Meng QH
Clin Chem; 2024 Apr; 70(4):669-679. PubMed ID: 38385453
[TBL] [Abstract] [Full Text] [Related]
5. A prospective study of
Shamim SA; Kumar N; Arora G; Jaswal S; Shalimar ; Gamanagatti S; Bal C
Ann Nucl Med; 2024 Feb; 38(2):103-111. PubMed ID: 37926772
[TBL] [Abstract] [Full Text] [Related]
6. Tumour Marker Requisition Pattern in a Tertiary Care Centre of Eastern Nepal.
Niraula A; Gelal B; Chaudhari RK; Das BK; Lamsal M
Kathmandu Univ Med J (KUMJ); 2022; 20(80):422-426. PubMed ID: 37795716
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive analysis of the biological functions of endoplasmic reticulum stress in prostate cancer.
Cen S; Jiang D; Lv D; Xu R; Hou J; Yang Z; Wu P; Xiong X; Gao X
Front Endocrinol (Lausanne); 2023; 14():1090277. PubMed ID: 36967783
[TBL] [Abstract] [Full Text] [Related]
8. Molecularly Imprinted Polymers for the Determination of cancer Biomarkers.
Pilvenyte G; Ratautaite V; Boguzaite R; Ramanavicius A; Viter R; Ramanavicius S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835517
[TBL] [Abstract] [Full Text] [Related]
9. Hepatoid prostatic carcinoma with adrenal metastasis and novel genetic alterations.
Ayala Soriano C; Benitez Barzaga M; Chhina A; Jain M; Nava VE
Diagn Cytopathol; 2022 Nov; 50(11):E310-E314. PubMed ID: 35765767
[TBL] [Abstract] [Full Text] [Related]
10. The Impact of a History of Different Other cancers on the Long-Term Outcomes of Patients with Intrahepatic Cholangiocarcinoma: A Population-Based Analysis.
Chai J; Kong J; Zhu K
Biomed Res Int; 2022; 2022():3970884. PubMed ID: 35257009
[TBL] [Abstract] [Full Text] [Related]
11. Genome-wide association study of serum tumor markers in Southern Chinese Han population.
Li X; Bai F; Wei X; Jin T; Li C; Zhang Y; Lin M; Zhou X; Xie Y; He C; Lin Q; He P; Chu S; Ding Y
BMC Cancer; 2022 Feb; 22(1):160. PubMed ID: 35144566
[TBL] [Abstract] [Full Text] [Related]
12. Tumor-Specificity Growth Factor Combined with Tumor Markers in Nuclear Medicine Imaging to Identify prostate cancer Osteonosus.
Zhang X; Chen Z
J Healthc Eng; 2021; 2021():7380120. PubMed ID: 34925738
[TBL] [Abstract] [Full Text] [Related]
13. Nanotechnology-based approaches for effective detection of tumor markers: A comprehensive state-of-the-art review.
Laraib U; Sargazi S; Rahdar A; Khatami M; Pandey S
Int J Biol Macromol; 2022 Jan; 195():356-383. PubMed ID: 34920057
[TBL] [Abstract] [Full Text] [Related]
14. afp peptide (afpep) as a potential growth factor for prostate cancer.
Zhu Z; West GR; Wang DC; Collins AB; Xiao H; Bai Q; Mesfin FB; Wakefield MR; Fang Y
Med Oncol; 2021 Nov; 39(1):2. PubMed ID: 34739644
[TBL] [Abstract] [Full Text] [Related]
15. Lectin Affinity Chromatography for the Discovery of Novel cancer Glycobiomarkers: A Case Study with PSA Glycoforms and prostate cancer.
Llop E; Peracaula R
Methods Mol Biol; 2022; 2370():301-313. PubMed ID: 34611876
[TBL] [Abstract] [Full Text] [Related]
16. Somatic-Type Yolk Sac Tumor Arising as a Predominant Component of Bladder Urothelial Carcinoma.
Collins K; Alkashash AM; Hwang M; Kaimakliotis HZ; Cheng L; Idrees MT
Int J Surg Pathol; 2022 Apr; 30(2):207-213. PubMed ID: 34255554
[TBL] [Abstract] [Full Text] [Related]
17. [Pathological features of primary extragonadal germ cell tumor of the prostate with small round blue cell morphology].
Gan HL; Wang QF
Zhonghua Bing Li Xue Za Zhi; 2021 Feb; 50(2):108-113. PubMed ID: 33535304
[No Abstract] [Full Text] [Related]
18. A label-free fluorescent aptasensor based on HCR and G-quadruplex DNAzymes for the detection of prostate-specific antigen.
Zhao R; Zhao L; Feng H; Chen X; Zhang H; Bai Y; Feng F; Shuang S
Analyst; 2021 Feb; 146(4):1340-1345. PubMed ID: 33367331
[TBL] [Abstract] [Full Text] [Related]
19. Differentiating cancer types using a urine test for volatile organic compounds.
Bannaga AS; Kvasnik F; Persaud K; Arasaradnam RP
J Breath Res; 2020 Dec; 15(1):017102. PubMed ID: 33086204
[TBL] [Abstract] [Full Text] [Related]
20. [
Kunikowska J; Cieślak B; Gierej B; Patkowski W; Kraj L; Kotulski M; Zieniewicz K; Królicki L
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):883-892. PubMed ID: 32885272
[TBL] [Abstract] [Full Text] [Related]
[Next]
